Skip to main content

Table 4 Univariate Cox proportional hazards analyses for survival

From: Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival

Variable

Hazard ratio

95% CI

p value

 

Lower

Upper

Age at biopsy, yr

1.040

0.977

1.108

0.220

Sex, female

0.432

0.122

1.526

0.193

Pack-year of smoking

0.993

0.978

1.008

0.367

Symptom onset, mo

1.001

0.994

1.009

0.737

Extent score on HRCT before AE

1.127

0.970

1.311

0.119

FVC before AE, % pred

0.989

0.956

1.023

0.514

FEV1/FVC, %

0.953

0.877

1.035

0.249

DLCO before AE, % pred

0.987

0.958

1.018

0.416

Resting PaO2, mmHg

0.999

0.961

1.039

0.961

Distance in six-minute walk test

0.998

0.992

1.005

0.609

Minimum SpO2 in six-minute walk test

0.960

0.884

1.043

0.338

Serum LDH, IU/L

1.003

0.997

1.008

0.305

Serum KL-6, U/mL

1.000

1.000

1.000

0.447

Serum SP-D, ng/mL

0.999

0.997

1.001

0.256

The GAP staging system before AE

1.089

0.639

1.854

0.754

Preceding treatments for IPF, +

0.913

0.399

2.088

0.829

Preceding oxygen therapy, +

1.662

0.678

4.074

0.267

P/F ratio at AE

0.999

0.994

1.003

0.565

Extent score on HRCT at AE

1.077

0.954

1.215

0.231

Period from admission to commencement of treatments for AE, day

1.104

0.985

1.237

0.090

Administration of Immunosuppressant for AE, +

1.403

0.548

3.593

0.481

Administration of Sivelestat sodium hydrate for AE, +

0.787

0.290

2.131

0.637

PMX-DHP, +

0.399

0.161

0.988

0.047

ΔWBC 2 days after commencement of treatments for AE, /μL

1.000

1.000

1.000

0.423

ΔNeutrophil 2 days after commencement of treatments for AE, /μL

1.000

1.000

1.000

0.607

ΔP/F ratio 2 days after commencement of treatments for AE

0.990

0.983

0.997

0.008

ΔLDH 2 days after commencement of treatments for AE, IU/L

1.006

1.002

1.011

0.009

ΔAngiopoietin-2 2 days after commencement of treatments for AE, pg/mL

1.000

1.000

1.001

0.307

  1. AE = acute exacerbation; IPF = idiopathic pulmonary fibrosis; FVC = forced vital capacity;
  2. FEV1 = forced expiratory volume in 1 second; DLCO = diffusion lung capacity for carbon monoxide; 6MWT = six-minute walk test; LDH = lactate dehydrogenase; KL-6 = Krebs von den Lungen-6; SP-D = surfactant protein D; P/F = PaO2/FiO2; HRCT = high-resolution computed tomography; PMX-DHP = direct hemoperfusion with a polymyxin B-immobilized fiber column.